MPH is the venture capital arm of Mitsubishi Tanabe Pharma Corp
Business Model:
Revenue: $23.8M
Employees: 51-200
Address: 33 Arch St
City: Boston
State: MA
Zip: 02110
Country: US
MPH is the venture capital arm of Mitsubishi Tanabe Pharma Corporation (MTPC). MPH invests in innovative companies developing novel therapeutics, platform technologies, and vaccines.
Contact Phone:
+16177374690
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2019 | Sonde Health | Series A | 0 |
9/2019 | Ribometrix | Equity | 7.8M |
5/2020 | QurAlis | Series A | 0 |
4/2021 | Outrun TX | Seed Round | - |
9/2020 | Korro Bio | Series A | 0 |
5/2010 | Pronota | Series B | 0 |
1/2012 | Pronota | Series C | 4.8M |
11/2015 | Viridian Therapeutics | Series C | 0 |
4/2018 | QurAlis | Seed Round | - |
11/2018 | Ribometrix | Series A | 30M |
4/2017 | Forge Therapeutics | Series A | 0 |
4/2011 | F-Star Therapeutics | Venture Round | 0 |
11/2018 | QurAlis | Seed Round | 5.5M |
9/2021 | SOLA Biosciences | Seed Round | - |
9/2021 | SOLA Biosciences | Seed Round | - |
1/2011 | Genocea Biosciences | Series B | 35M |
10/2013 | F-Star Therapeutics | Series A | 0 |
3/2015 | Thrasos | Series D | 21M |
10/2009 | Covagen | Seed Round | - |
5/2011 | Genkyotex | Series C | 20.4M |
11/2010 | Covagen | Series A | 6.3M |
10/2017 | Ribometrix | Seed Round | 7.5M |
1/2012 | Syndexa Pharmaceuticals | Series B | 8.5M |
7/2012 | Genkyotex | Series C | 25.6M |
11/2009 | FerroKin Biosciences | Venture Round | 15M |
1/2010 | F-Star Therapeutics | Series A | 11.5M |
1/2009 | Intradigm Corporation | Series B | 0 |
12/2020 | Capsigen | Seed Round | - |
10/2012 | Thrasos | Series C | 35M |
10/2009 | Pronota | Series B | 1.9M |
6/2011 | PharmEste | Series B | 0 |
10/2012 | Genocea Biosciences | Series C | 30M |
6/2010 | FerroKin Biosciences | Series B | 12M |
3/2023 | QurAlis | Series B | 0 |
5/2023 | PharmEnable | Seed Round | 0 |
5/2021 | Libero Thera | Venture Round | 0 |
1/2021 | Blacksmith Medicines | Seed Round | - |
12/2009 | Genocea Biosciences | Series B | 25.7M |
12/2013 | Covagen | Series B | 0 |
1/2022 | Korro Bio | Series B | 0 |
9/2016 | Rigontec | Series A | 16.9M |
5/2023 | PharmEnable | Seed Round | 0 |
3/2023 | QurAlis | Series B | 0 |
1/2022 | Korro Bio | Series B | 0 |
9/2021 | SOLA Biosciences | Seed Round | - |
5/2021 | Libero Thera | Venture Round | 0 |
4/2021 | Outrun TX | Seed Round | - |
1/2021 | Blacksmith Medicines | Seed Round | - |
12/2020 | Capsigen | Seed Round | - |
9/2020 | Korro Bio | Series A | 0 |
5/2020 | QurAlis | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|